Stem cell co Mesoblast reports PhIII trial success in children with GVHD – Endpoints News
Endpoints News |
Stem cell co Mesoblast reports PhIII trial success in children with GVHD
Endpoints News The company, called Mesoblast $MESO, was testing its allogeneic mesenchymal stem cell product called remestemcel-L. The off-the-shelf therapy is meant to treat Graft Versus Host Disease, a condition that often arises in blood cancer patients who've had … |
